Tags:Science & TechUPSC
For Prelims: Hepatitis B Virus (HBV), Epigenetics, DNA Methylation, CRISPR-Cas9, Functional Cure, Therapy Name, Key Mechanism, Technology Used
For Mains: Paradigm shift in antiviral therapy; Epigenetic silencing; Transient mRNA delivery; Precision medicine for chronic infections
Source:
Why in the news?
Researchers have developed an experimental gene therapy, CRMA-1001, which silences the hepatitis B virus (HBV) DNA in liver cells using epigenetic modification, offering a potential functional cure. Unlike current treatments, it uses CRISPR-Cas9 to target and methylate the viral genome, suppressing viral activity without eliminating it. In mouse studies, three doses led to undetectable viral DNA in 90% of animals after six months.
Summary
- CRMA-1001 is a novel gene therapy for Hepatitis B that uses epigenetic silencing (DNA methylation) to suppress the virus, achieving a 'functional cure' where the virus is present but inactive.
- The therapy combines CRISPR-Cas9 as a 'locator' to target viral DNA and methylation machinery as an 'effector', delivered via an mRNA platform, making its action transient.
- Published in Nature Biomedical Engineering, the study shows promising results in mice, but long-term efficacy and human trials (Phase I/II ongoing) are needed to confirm its potential as a therapy.
Highlights
Epigenetic Therapy
CRMA-1001 silences Hepatitis B virus by adding methyl groups to its DNA, switching off viral genes without removing the DNA.
CRISPR Delivery
The therapy uses CRISPR-Cas9 to precisely locate viral DNA and deliver methylation enzymes, all packaged in a transient mRNA delivery system.
Functional Cure
It aims for a functional cure, where the virus persists but is suppressed below detectable levels, unlike current treatments that rarely eliminate viral DNA.
Context / Background
Hepatitis B is a major global health challenge, with current antiviral treatments (nucleos(t)ide analogues) rarely eliminating the covalently closed circular DNA (cccDNA) of the virus from liver cells. This residual DNA allows the virus to rebound. The discovery of 5-methylcytosine in 1925 and the 1975 hypothesis by Holliday and Pugh that DNA methylation controls gene expression laid the foundational science for this epigenetic approach to therapy.
Core Analysis & Implications
CRMA-1001 represents a paradigm shift from directly attacking the virus to making the host cell ignore it. By methylating the viral DNA, it mimics a natural epigenetic silencing mechanism. The use of an mRNA platform ensures the therapy is transient, reducing risks of off-target effects. The 90% suppression rate in mice after three doses is significant, but the key limitation is the persistence of viral DNA, leaving a theoretical possibility of reactivation, which long-term studies must address.
Future Outlook / Way Forward
The ongoing Phase I/II clinical trial will determine safety and long-term efficacy in humans. Success could lead to the first approved epigenetic therapy for a chronic viral infection, with potential applications for other viruses that integrate into host DNA (e.g., HIV). Regulatory approval would require demonstrating sustained suppression over many years and establishing protocols for monitoring potential late reactivation.
Background GK
Textbook concepts you need to understand this news
- Hepatitis B Virus (HBV)
- A DNA virus that causes liver infection, which can become chronic and lead to cirrhosis or liver cancer. It is transmitted via bodily fluids.
- Epigenetics
- The study of heritable changes in gene expression that do not involve changes to the underlying DNA sequence. Mechanisms include DNA methylation and histone modification.
- DNA Methylation
- A biochemical process involving the addition of a methyl group (-CH3) to the cytosine base in DNA, typically associated with gene silencing.
- CRISPR-Cas9
- A gene-editing technology that allows precise modification of DNA within organisms. It uses a guide RNA (gRNA) to target a specific DNA sequence and the Cas9 enzyme to cut it.
- Functional Cure
- A state in which a pathogen is not completely eliminated from the body but is controlled to such low levels that it does not cause disease or symptoms, and standard tests cannot detect it.
Facts to remember
Tap a card to see the answer. Try to recall it first.
How exams will ask this
- Data: 90% of mice showed undetectable viral DNA after 3 doses of CRMA-1001.
- Nodal Technology: Combination of CRISPR-Cas9 (locator) and methylation machinery (effector).
- Publication: Findings published in 'Nature Biomedical Engineering' on 21 September 2026.
Don't make this mistake!
Confusing 'functional cure' (virus suppressed but present) with 'sterilizing cure' (virus eliminated). They may also swap the roles of 'locator' (CRISPR) and 'effector' (methylation proteins) or misattribute the delivery platform (e.g., viral vector instead of mRNA).
Write these in mains answers
- Paradigm shift in antiviral therapy
- Epigenetic silencing
- Transient mRNA delivery
- Precision medicine for chronic infections
Practice questions
Pick an answer, then read the explanation.
- Q1Easy
The experimental therapy CRMA-1001, mentioned in the news, is designed to treat which viral infection?
Explanation: The article explicitly states that CRMA-1001 is an experimental therapy to treat hepatitis B infection by silencing the viral DNA in liver cells.
- Q2Hard
Consider the following statements regarding the CRMA-1001 therapy:
- 1.It aims to achieve a sterilizing cure by completely eliminating the hepatitis B virus DNA from liver cells.
- 2.The therapy uses the CRISPR-Cas9 system as an 'effector' to add methyl groups to the viral DNA.
- 3.The therapeutic components are delivered using an mRNA platform, making the system's action transient.
Which of the statements given above is/are correct?
Explanation: Statement 1 is incorrect: CRMA-1001 aims for a functional cure, not a sterilizing cure; the viral DNA persists but is silenced. Statement 2 is incorrect: CRISPR-Cas9 is used as the 'locator' to find the viral DNA, not the 'effector' that adds methyl groups. Statement 3 is correct as per the article, which states the system is delivered on an mRNA platform and is transient.
- Q3Medium
According to the study on CRMA-1001 in mice, what percentage of animals showed viral DNA levels below detection six months after three doses of the therapy?
Explanation: The article states: "six months after the first dose, as many as 90% of the animals had less viral DNA than could be detected." The other options are plausible but incorrect distractors.
- Q4Medium
What is the primary innovative mechanism of action of the CRMA-1001 therapy for Hepatitis B?
Explanation: The core innovation of CRMA-1001, as described in the article, is that it silences the viral DNA through epigenetic modification (methylation), rather than directly targeting the virus or boosting immunity. This approach aims to switch off the viral genes.
Frequently asked questions
1. What is the therapy Name?
CRMA-1001
2. What is the key Mechanism?
Epigenetic silencing via DNA methylation of viral genome
3. What is the technology Used?
CRISPR-Cas9 (locator) + Methylation machinery (effector)
4. What is the delivery Platform?
mRNA platform (transient delivery)
5. What is the study Result (Mice)?
90% of animals had undetectable viral DNA after 3 doses in 6 months
6. What is the published Journal & Date?
Nature Biomedical Engineering, 21 September 2026
7. What is the current Status?
Phase I/II clinical trial ongoing
8. What is the key Viral Proteins Targeted?
HBsAg and HBeAg
All sources
- Original29 October 2026 · Read story
